Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.
GSK2140944 is a novel bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and methicillin-resistant Staphylococcus aureus. This quality control study was performed to establish ranges for selected control strains: S. aureus ATCC 29213 and ATCC 25923, Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247, and Streptococcus pneumoniae ATCC 49619. The control ranges will be crucial for the accurate evaluation of GSK2140944 potency as it progresses through clinical trial development.
JMI Laboratories, North Liberty, Iowa, USA jim-ross@jmilabs.com.
James E
JE
Ross
GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Nicole E
NE
Scangarella-Oman
JMI Laboratories, North Liberty, Iowa, USA.
Robert K
RK
Flamm
JMI Laboratories, North Liberty, Iowa, USA Tufts University School of Medicine, Boston, Massachusetts, USA.
Ronald N
RN
Jones
D000890:Anti-Infective Agents / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards*; D015394:Molecular Structure; D011786:Quality Control; D059003:Topoisomerase Inhibitors / Q000494:pharmacology*
D000890:Anti-Infective Agents; D059003:Topoisomerase Inhibitors